Early hepatitis B virus (HBV) infection is a major public health problem in Africa. The World Health Organization (WHO) recommends the vaccination of neonates at birth to prevent HBV mother-to-child transmission (MTCT). However, vaccination may not be sufficient in infants born to mothers with high HBV levels. This study will determine whether treating highly infectious HBV-pregnant women with tenofovir in addition to the WHO-recommended intervention (HBV birth dose (BD) vaccine to their infants) is more effective than the BD vaccine alone to prevent HBV MTCT in Africa.
To learn more, contact us.